93 related articles for article (PubMed ID: 2308979)
21. Purging of myeloma cells from bone marrow using monoclonal antibodies and magnetic immunobeads in combination with 4-hydroperoxycyclophosphamide.
Shimazaki C; Inaba T; Murakami S; Fujita N; Nakagawa M; Gulati SC; Fried J; Clarkson BD; Wisniewolski R; Wang CY
Prog Clin Biol Res; 1990; 333():311-9. PubMed ID: 2308988
[No Abstract] [Full Text] [Related]
22. Characterization of a monoclonal antibody having selective reactivity with normal and neoplastic plasma cells.
Tong AW; Lee JC; Stone MJ
Blood; 1987 Jan; 69(1):238-45. PubMed ID: 3098320
[TBL] [Abstract][Full Text] [Related]
23. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage.
Bellamy WT; Dalton WS; Kailey JM; Gleason MC; McCloskey TM; Dorr RT; Alberts DS
Cancer Res; 1988 Nov; 48(22):6365-70. PubMed ID: 3180056
[TBL] [Abstract][Full Text] [Related]
24. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
[TBL] [Abstract][Full Text] [Related]
25. Elimination of B-lymphoma cells from human bone marrow: model experiments using monodisperse magnetic particles coated with primary monoclonal antibodies.
Kvalheim G; Fodstad O; Pihl A; Nustad K; Pharo A; Ugelstad J; Funderud S
Cancer Res; 1987 Feb; 47(3):846-51. PubMed ID: 3492268
[TBL] [Abstract][Full Text] [Related]
26. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
27. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture.
Greenberger JS; Rothstein L; DeFabritiis P; Bregni M; Bast R; Ritz J; Nadler LM; Lipton JM; Sakakeeny MA
Cancer Res; 1985 Feb; 45(2):758-67. PubMed ID: 3967246
[TBL] [Abstract][Full Text] [Related]
28. Optimal conditions for in vitro T cell depletion of human bone marrow by Campath-1a plus complement as demonstrated by limiting dilution analysis.
Frame JN; Sheehy D; Cartagena T; Cirrincione C; O'Reilly RJ; Dupont B; Kernan NA
Bone Marrow Transplant; 1989 Jan; 4(1):55-61. PubMed ID: 2784335
[TBL] [Abstract][Full Text] [Related]
29. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
30. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
[TBL] [Abstract][Full Text] [Related]
31. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.
Bellamy WT; Dorr RT; Dalton WS; Alberts DS
Cancer Res; 1988 Nov; 48(22):6360-4. PubMed ID: 3180055
[TBL] [Abstract][Full Text] [Related]
32. Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement.
Haleem A; Kurtzberg J; Olsen GA; Rhinehardt-Clark A; Leslie DS; Ray L; Smith CA; Peters WP; Haynes BF; Bast RC
Cancer Res; 1987 Sep; 47(17):4608-12. PubMed ID: 3113721
[TBL] [Abstract][Full Text] [Related]
33. Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine.
Porter CW; Ganis B; Rustum Y; Wrzosek C; Kramer DL; Bergeron RJ
Cancer Res; 1994 Nov; 54(22):5917-24. PubMed ID: 7954423
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein.
Dalton WS; Durie BG; Alberts DS; Gerlach JH; Cress AE
Cancer Res; 1986 Oct; 46(10):5125-30. PubMed ID: 2875788
[TBL] [Abstract][Full Text] [Related]
35. Addition of a bone marrow "facilitating cell" population increases stem cell-derived cobblestone area formation in impaired long-term bone marrow culture stroma.
Yaroslavskiy B; Colson Y; Ildstad S; Parrish D; Boggs SS
Exp Hematol; 1998 Jul; 26(7):604-11. PubMed ID: 9657135
[TBL] [Abstract][Full Text] [Related]
36. In vitro maintenance and retroviral transduction of human myeloma cells in long-term marrow cultures.
Stewart AK; Prince HM; Cappe D; Chu P; Lutzko C; Sutherland DR; Dubé ID
Cancer Gene Ther; 1997; 4(3):148-56. PubMed ID: 9171933
[TBL] [Abstract][Full Text] [Related]
37. Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells.
Ayuk FA; Fang L; Fehse B; Zander AR; Kröger N
Exp Hematol; 2005 Dec; 33(12):1531-6. PubMed ID: 16338496
[TBL] [Abstract][Full Text] [Related]
38. A combined approach for purging multidrug-resistant leukemic cell lines in bone marrow using a monoclonal antibody and chemotherapy.
Aihara M; Aihara Y; Schmidt-Wolf G; Schmidt-Wolf I; Sikic BI; Blume KG; Chao NJ
Blood; 1991 May; 77(9):2079-84. PubMed ID: 1673356
[TBL] [Abstract][Full Text] [Related]
39. Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads.
Shimazaki C; Wisniewski D; Scheinberg DA; Atzpodien J; Strife A; Gulati S; Fried J; Wisniewolski R; Wang CY; Clarkson BD
Blood; 1988 Oct; 72(4):1248-54. PubMed ID: 3167207
[TBL] [Abstract][Full Text] [Related]
40. The nature of cells generating human myeloma colonies in vitro.
Hamburger AW; Kim MB; Salmon SE
J Cell Physiol; 1979 Feb; 98(2):371-6. PubMed ID: 422663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
